RNA vs. NAMS, RCKT, GLPG, AMRX, EVO, GPCR, AMPH, AGIO, KROS, and SNDX
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include NewAmsterdam Pharma (NAMS), Rocket Pharmaceuticals (RCKT), Galapagos (GLPG), Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Keros Therapeutics (KROS), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
NewAmsterdam Pharma (NASDAQ:NAMS) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 3 articles in the media. NewAmsterdam Pharma's average media sentiment score of 1.47 beat Avidity Biosciences' score of 0.08 indicating that Avidity Biosciences is being referred to more favorably in the news media.
NewAmsterdam Pharma has higher revenue and earnings than Avidity Biosciences.
NewAmsterdam Pharma presently has a consensus target price of $33.25, suggesting a potential upside of 47.32%. Avidity Biosciences has a consensus target price of $36.33, suggesting a potential upside of 42.04%. Given Avidity Biosciences' higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Avidity Biosciences.
Avidity Biosciences received 123 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.11% of users gave Avidity Biosciences an outperform vote.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 2.0% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NewAmsterdam Pharma has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -2,219.87%. Avidity Biosciences' return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.
NewAmsterdam Pharma has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Summary
NewAmsterdam Pharma beats Avidity Biosciences on 9 of the 14 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
